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ABSTRACT 26 
The Q80K polymorphism in the HCV NS3 enzyme reduces susceptibility to simeprevir and 27 
other novel protease inhibitors. The study aimed to determine the prevalence of Q80K in 28 
treatment-naïve HCV-1a carriers in the North-West (NW) and South-East (SE) of England, 29 
investigate occurrence of Q80K as a minority variant, and characterise viral phylogeny. Plasma 30 
samples from subjects that were naïve to anti-HCV therapy underwent conventional (Sanger) 31 
and deep (Illumina-Miseq, 1% interpretative cut-off) sequencing of NS3. Q80K occurred in 32 
44/238 subjects (18.5%, 95% confidence interval 13.6%-23.4%), including 19/70 (27.1%) in 33 
the NW and 25/168 (14.9%) in the SE (p=0.0425), with no difference by HCV RNA load or 34 
HIV status. Q80K frequencies in reads of samples that underwent Illumina sequencing 35 
were >40% in all cases. Among subjects with Q80K, 5/44 (11.4%) showed one additional 36 
major resistance-associated mutation in NS3 detected at mutant frequency above (V36L, 37 
V55A) or below (V36M) 10%. Phylogenetic analyses identified the two recognised HCV-1a 38 
lineages with (clade I) and without (clade II) Q80K. Overall, 148/238 (62.2%) sequences 39 
occurred within regional or inter-regional clusters, each comprising 3-20 sequences. There 40 
was no unique clustering of English sequences relative to strains from continental Europe and 41 
North America. In conclusion, Q80K was found at high prevalence among treatment-naïve 42 
HCV-1a carriers in England, and was reliably detected by conventional sequencing, with no 43 
increased detection by deep sequencing. English sequences were highly interspersed with 44 
sequences from elsewhere in Europe (clade II) and North America (clade I), and their 45 
phylogeny was consistent with multiple introductions from different areas.  46 
47 
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INTRODUCTION 48 
The HCV NS3 protease enzyme exhibits a high degree of genetic variability and only 47% of 49 
its amino acids are conserved among circulating HCV genotypes.[1] NS3 genetic heterogeneity 50 
and the associated molecular and structural differences influence HCV susceptibility to 51 
protease inhibitors (PIs), including licensed first-generation (telaprevir, boceprevir) and 52 
second-generation (simeprevir) compounds. HCV variants with reduced PI susceptibility have 53 
been observed in treatment-naive patients.[1-10] Among these, the glutamine to lysine 54 
substitution at codon 80 (Q80K) reduces susceptibility to simeprevir in vitro [2, 4, 11] and was 55 
also seen to reduce virological responses to simeprevir plus pegylated interferon alpha and 56 
ribavirin (P/R) in clinical studies.[12-14] Screening for Q80K is therefore recommended before 57 
starting simeprevir.[15] 58 
 59 
The prevalence of Q80K among PI-naïve subjects varies by HCV genotype and subtype. An 60 
analysis of global NS3 sequences deposited in GenBank reported Q80K in 42% of HCV-1a 61 
strains, and also detected a high prevalence in HCV-5 and HCV-6 strains.[1] Among HCV-1a 62 
strains, prevalence of Q80K ranges between 3% and 47% by geographical location, exceeding 63 
40% in North America.[2, 4] Reported prevalence is 20% overall across Europe, although 64 
differing markedly by country.[7-9]  Most studies to date have produced prevalence estimates 65 
using conventional (Sanger) sequencing, which allows detection of virus variants present at a 66 
frequency ≥20% within a patient’s sample.  67 
 68 
This study had three aims. Firstly, to determine the prevalence of Q80K in NS3 sequences 69 
obtained from HCV-1a carriers attending for care in two regions of England in the United 70 
Kingdom(UK). A further aim was to investigate the occurrence of Q80K as a low frequency 71 
variant by deep sequencing, and thereby both gain insights into the viral quasispecies and 72 
determine whether conventional sequencing offers sufficient sensitivity for screening 73 
simeprevir candidates for the presence of Q80K. The third aim was to determine the phylogeny 74 
of NS3 sequences in relation to publically available sequences from the rest of Europe and 75 
North America.   76 
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METHODS 77 
Study population 78 
The study was performed retrospectively using stored plasma samples from consecutive adults 79 
that in 2006-2014 attended for care at the Royal Liverpool University Hospital in Liverpool 80 
(North-West region) and at King’s College Hospital, Chelsea & Westminster Hospital, and 81 
Charing Cross Hospital in London (South-East region). Eligible patients were infected with 82 
HCV-1a based on the genotyping method available at the local National Health System 83 
diagnostic laboratory; the assignment was confirmed by analysis of the NS3 sequences 84 
produced in this study. Patients were naïve to all anti-HCV therapy. HIV status and HCV 85 
RNA load were retrieved from the clinics’ databases. Ethics permission was granted by the 86 
South Berkshire Regional Ethics Committee to conduct the study after removing personal 87 
identifiers from the samples. 88 
 89 
Sanger sequencing 90 
HCV RNA was extracted with Nuclisens easyMAG (bioMérieux, Netherlands) and cDNA 91 
synthesis was performed with the Qiagen OneStep RT-PCR Kit (Hilden, Germany) with 92 
forward primer 3278 [GGAGACCAAGMTCATCACSTGG] and reverse primer 4032 93 
[GCTCTTRCCGCTGCCRGTGGG]. The first-round amplicon was subjected to nested PCR 94 
using the Qiagen HotStarTaq Kit with forward primer 3307 95 
[ACACCGCSGCGTGYGGKGACAT] and reverse primer 4014 96 
[GGRGCRTGYAGRTGGGCCAC]. The second-round 727bp amplicon (aa180 of NS2 to 97 
aa204 of NS3) was purified with the Qiagen QIAquick PCR Purification Kit and sequenced 98 
using the BigDye Terminator Cycle Sequencing Kit v3.1 on the ABI Prism 3730 Genetic 99 
Analyser (Applied Biosystems®, USA). Consensus sequences were assembled using SeqScape 100 
(v2.7) and analysed with the geno2pheno system (http://hcv.geno2pheno.org/index.php; March 101 
2015 version) for the presence of HCV resistance-associated mutations (RAMs).  102 
 103 
Deep sequencing 104 
HCV RNA was extracted with QiasymphonySP (Qiagen) using the Qiagen 105 
DSPVirus/Pathogen Midi Kit and the CellFree_500_V4 protocol; cDNA was produced using 106 
the ImProm II Reverse Transcription System (Promega, USA) and random primers. NS3 was 107 
amplified using Q5 High-Fidelity DNA Polymerase (New England Biolabs, USA) and the 108 
above primers. PCR products were purified using AMPure XP Beads (Beckman Coulter, USA) 109 
before quantification with the Quant-iT dsDNA High Sensitivity Kit (Life Technologies, USA) 110 
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on a Qubit 2.0 Fluorometer (Life Technologies). The Nextera XT Sample Preparation Kit 111 
(Illumina, USA) was used for library preparation and pooled amplicon libraries were 112 
sequenced on Illumina MiSeq using v2 reagents. Data generation and initial analysis were 113 
carried out at the Centre for Genomic Research at the University of Liverpool. Adapter 114 
sequences were trimmed from the Illumina reads using Cutadapt v1.2.1[16]; further trimming 115 
was done using Sickle v1.2 (http://github.com/najoshi/sickle) applying a minimum window 116 
quality score of 20. BAMStats (http://sourceforge.net/projects/bamstats/files/) was used to 117 
calculate the read statistics. Variants were analysed using the VirVarSeq pipeline,[17] which 118 
utilises the quality of the run and individual bases to filter poor quality bases and reduce false 119 
positive rates. A 727bp region of a HCV-1a molecular clone encoding full-length NS3 was 120 
amplified and sequenced in four replicates in order to estimate the assay error rate. The plasmid 121 
control yielded an average of 174,799 reads, with a mean coverage of 46,268 reads per 122 
nucleotide. The error rate, calculated by counting false substitution reads at the codon level of 123 
the molecular clone [18], was mean 0.6% (SD 0.2%) over NS3 amino acids 1-181. 124 
 125 
Phylogenetic analysis 126 
Reference HCV-1a sequences and all available HCV-1a NS3 sequences from North America 127 
and Europe with confirmed genotype assignment and country of origin were retrieved from the 128 
Los Alamos HCV database (hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html; accessed 129 
on 8 March 2015) (supplementary file). All sequences, including those produced in this 130 
study (Sanger sequences and NGS consensus sequences with 1% interpretative cut-off), 131 
were aligned pairwise against the HCV-1a reference genome H77 (accession no. NC_004102) 132 
using MEGA v.6. The alignment was trimmed to codon positions 1-194 of NS3 (nucleotides 133 
3421-4014 of H77). Sequences with gaps or ambiguous nucleotides affecting ≥50% of the 134 
targeted region or where codon 80 was missing or ambiguous were removed (n=3), yielding a 135 
total of 1162 NS3 sequences for analysis. Two maximum-likelihood (ML) phylogenies were 136 
estimated with and without the 80 codon, using a general-time reversible nucleotide 137 
substitution model with gamma-distributed among-site rate variation and the ML method as 138 
implemented in PHYML v.3.0.[19, 20] Phylogenetic support was evaluated using a bootstrap 139 
approach and a total of 1000 bootstrap replicates were generated using the FastTree v.2.1.7 140 
software;[21] local branch support was calculated by the Shimodaira–Hasegawa-like (SH-like) 141 
test. Phylogenies were visualized and annotated in FigTree (http://tree.bio.ed.ac.uk). Clusters 142 
(≥3 sequences) were identified by a bootstrap support >75% and were defined as regional if 143 
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comprising sequences unique to either the NW or the SE, and inter-regional if including 144 
sequences from both regions. 145 
 146 
Statistical analysis 147 
Descriptive statistics were used to analyse the prevalence of mutants in the study population 148 
(as the proportion of subjects showing the mutation) and the frequency of mutants in each 149 
patient’s sample (as the proportion of deep sequencing reads showing the mutation). Proportion 150 
of subjects with Q80K by geographic location and HIV status were compared by Fisher’s exact 151 
test. The Mann-Whitney U test was used to compare the HCV RNA load of patients with and 152 
without Q80K. The analysis was performed using SPSS v.21.  153 
 154 
RESULTS 155 
Study population  156 
Overall 238 adults (median age 44 years, with no difference by region) infected with HCV-1a 157 
were studied, including 70/238 (29.4%) in the North-West (NW) and 168/238 (70.6%) in the 158 
South-East (SE). At the time of testing, HCV RNA load was median 6.3 log10 IU/ml 159 
(interquartile range,IQR 5.8-6.8), without differences between the two regions. Subjects were 160 
naïve to all anti-HCV therapy. A total of 61/238 (25.6%) subjects, all from the SE, were co-161 
infected with HIV.  162 
 163 
Q80K prevalence by Sanger sequencing 164 
Overall, Q80K was detected in 44/238 subjects, yielding a prevalence of 18.5% (95% 165 
confidence interval, CI 13.6%-23.4%)(Table 1). Samples from two of the 44 subjects had a 166 
mixed first base at codon 80 (Q80Q/K). The median HCV RNA load was 6.4 (IQR 5.8-6.7) 167 
vs. 6.3 (IQR 5.8-6.8) log10 IU/ml in samples with vs. samples without Q80K, respectively 168 
(p=0.63). The prevalence of Q80K was 19/70 (27.1%) in the NW and 25/168 (14.9%) in the 169 
SE (p=0.043). When comparing results by HIV status in the SE, Q80K prevalence was 18/107 170 
(16.8.%) in HCV mono-infected subjects and 7/61 (11.5%) in HCV/HIV co-infected subjects 171 
(p=0.379). Table 1 shows other major and minor NS3 RAMs detected by Sanger sequencing.  172 
 173 
Q80K prevalence by deep sequencing 174 
A total of 178/238 (74.8%) samples underwent deep sequencing, comprising 28/178 (15.7%) 175 
with and 150/178 (84.3%) without Q80K by Sanger sequencing. An average of 58,585 reads 176 
per sample was obtained (median 53,413; IQR 40,740-70,255) with an average coverage per 177 
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nucleotide of 16,107. Prevalence of Q80K was 27/178 (15.2% 95% CI 9.9%-20.5%). All 28 178 
samples showing Q80K by Sanger sequencing also showed the mutation by deep sequencing, 179 
usually (26/28 samples) with mutant frequencies of ≥98%. Of the two samples showing 180 
Q80Q/K by Sanger sequencing, one had a Q:K ratio of 54:46, and the other showed Q, K and L 181 
at a ratio of 57:41:2. Of 150 samples lacking Q80K by Sanger sequencing, none showed the 182 
mutation by deep sequencing when applying an interpretative cut-off of ≥1% for the frequency 183 
of mutants within the reads, as usually recommended.[22]  Prevalence of Q80K increased when 184 
the interpretative cut-off was lowered, and was 3/150 (2%) for Q80K occurring at a frequency 185 
between ≥0.5% and <1%, and 15/150 (10%) at a frequency ≥0.2% and <0.5%. These cut-offs 186 
however fell within the estimated error rate of the assay (0.6%, SD 0.2%).  187 
 188 
Deep sequencing (interpretative cut-off ≥1%) identified additional NS3 RAMs that had not 189 
been observed by Sanger sequencing and which occurred at frequencies between 1% and 6% 190 
(Table 1). Among the 44 subjects with Q80K, 4/44 (9.1%) had one additional major NS3 191 
RAM at frequency >10% including V36L in 3/44 (6.8%) and V55A in 1/44 (2.3%). In 192 
addition 1/44 (2.3%) subjects had V36M detected only by Illumina at a frequency of 3%.  193 
 194 
Phylogeny of NS3 sequences 195 
HCV-1a strains separated into the two recognised distinct lineages with and without Q80K.[23, 196 
24] The sequences harbouring Q80K at frequency <1% did not align with the Q80K lineage 197 
(data not shown). There was no unique clustering of the study English sequences (Figure 1), 198 
rather the sequences were interspersed with sequences from the rest of Europe and North 199 
America, and the phylogeny was consistent with multiple introductions from different areas. 200 
With the English sequences, four NW, eight SE, and 11 inter-regional clusters were identified, 201 
each consisting of 3-20 sequences (Figure 2). In total, 148/238 (62.2%) sequences (49/70, 202 
70.0% in the NW and 99/168, 58.9% in the SE) were circulating as regional or inter-regional 203 
clusters.  204 
 205 
DISCUSSION 206 
This study detected the NS3 polymorphism Q80K at high prevalence among treatment-naïve 207 
HCV-1a carriers attending for care in England, particularly in the North-West where 208 
prevalence reached 27.1%. Previously published data from the UK include a small cohort of 38 209 
HIV-positive patients with acute HCV-1a infection, of which 16% had Q80K.[6] A larger 210 
study analysed 159 subjects with HCV-1a that were enrolled in Phase II/III studies of 211 
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telaprevir and simeprevir, of which 23% showed Q80K[8]; these sequences are not available 212 
for analysis however, as to date they have not been deposited in the GenBank or the Los 213 
Alamos database. These data indicate that HCV-1a strains circulating in the UK have the 214 
highest prevalence of Q80K observed in Europe. 215 
 216 
In this study the prevalence of Q80K varied by geographical region, while showing no 217 
difference by HIV status. Prevalence rates also show marked geographical variability in the 218 
rest of Europe.[7-9] The variable prevalence has not been linked to race or ethnicity [8], but 219 
rather is consistent with the circulation of two distinct HCV-1a lineages with and without 220 
Q80K.[23, 24] The Q80K-carrying lineage is believed to have originated in the United States 221 
in the 1940s.[23] In this study, the maximum likelihood phylogenetic analysis confirmed the 222 
two HCV-1a lineages, and detected multiple introductions of the two lineages in the UK, with 223 
wide interspersing of the English strains with other European and North American strains. 224 
Most HCV-1a sequences occurred as regional or mixed regional clusters, however, suggesting 225 
that for this cohort the majority of transmission events occurred within the UK. 226 
 227 
The deep sequencing analysis showed that Q80K mutants occurred at high frequency (>40%) 228 
in the patients’ samples, allowing detection by conventional sequencing in all cases. This 229 
finding is consistent with the observation that Q80K mutants have replication capacity similar 230 
to that of wild-type virus, which allows transmissibility and persistence at high frequency 231 
within the viral quasispecies despite the absence of drug selective pressure. There were no 232 
samples showing Q80K at a frequency below the detection threshold of Sanger sequencing 233 
(≥10-20%) and above the typical ≥1% interpretative cut-off for deep sequencing, which is 234 
recommended to differentiate biologically meaningful mutations from those caused by 235 
methodological errors.[22] When applying less stringent cut-offs (0.5% or 0.2%) the 236 
proportion of samples showing Q80K by deep sequencing increased. A previous study 237 
similarly found that among 21 subjects with Q80K detected by deep sequencing, four showed 238 
the mutation at a frequency <1%.[10] The estimated error rate of the assay (0.6%) and the 239 
observation that sequences showing Q80K at a frequency <1% did not align within the Q80K 240 
lineage suggest that the detection of Q80K at frequency <1% was spurious. Furthermore, it 241 
remains to be determined whether any Q80K variant occurring at low frequency has 242 
clinical relevance. 243 
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Q80K reduces HCV-1a susceptibility to simeprevir by 8-11 fold in vitro.[4, 8, 11] In HCV-1a 244 
infection, sustained virological responses (SVR) to combination therapy with simeprevir plus 245 
P/R are reduced by the presence of baseline Q80K in both treatment-naïve subjects (from 84% 246 
to 58%) and prior relapsers (from 79% to 47%).[11-13] The impact of Q80K on the 247 
combination of simeprevir plus sofosbuvir was not immediately apparent in some reported 248 
studies.[25] However, a phase III, open-label, single-arm study with simeprevir plus 249 
sofosbuvir in cirrhotic patients with HCV-1 recently reported that SVR rates were higher 250 
in subjects without Q80K (92%) versus those with the mutation (74%).[26] Q80K has no 251 
effects on susceptibility to telaprevir and boceprevir [4], but may have an effect on responses to 252 
asunaprevir.[27] Q80K also confers small reductions (~3-fold) in susceptibility to faldaprevir 253 
and paritaprevir in vitro, without necessarily affecting response rates.[28] The Q80L and Q80R 254 
mutations were detected in some subjects, usually at low frequency. Their significance is 255 
unclear. In vitro, the mutations confer 2-fold and 7-fold reductions in susceptibility to 256 
simeprevir, respectively.[11] Q80R has also been observed in a small number of patients 257 
experiencing failure of simeprevir therapy, when it occurred alongside major resistance 258 
mutations at position 155 and/or position 168.[29] Other major NS3 RAMs occurred at codons 259 
36, 54, 55, 168, and 170, which is consistent with previous observations.[1-6, 9, 30]. A small 260 
subset of five subjects had Q80K plus one other major RAM in NS3.   261 
 262 
In summary, we found a high prevalence of Q80K in HCV-1a carriers with and without HIV 263 
accessing care in two regions of the UK, thus complementing estimates from elsewhere in 264 
Europe. While deep sequencing increased detection of Q80K, mutants missed by Sanger 265 
sequencing occurred at frequency ≤0.5% and detection seemed a likely technical artefact. 266 
There was evidence of a high degree of interspersing of UK sequences with sequences from 267 
elsewhere in Europe and North America, although the phylogeny indicated that most 268 
transmission events occurred in the UK. Investigation of full viral genomes will elucidate 269 
HCV-1a transmission networks and gain data to inform control strategies.  270 
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Table 1. Prevalence of NS3 resistance-associated mutations (RAMs) in treatment-naïve HCV-271 
1a carriers according to modality of detection (Sanger or Illumina) and frequency of the 272 
mutant as determined by Illuminaa 273 
RAMs Sanger/Illumina >10%  Illumina 1-10%  
n (%) n (%) 
Total tested 238 (100) 178 (100) 
36 M   1 (0.4)   2 (1.1) 
36 L   5 (2.1) 0 (0) 
54 S   9 (3.8) 0 (0) 
55 A 10 (4.2) 0 (0) 
80 K   44 (18.5) 0 (0) 
80 L    1 (0.4)   4 (2.2) 
80 R 0 (0)    3 (1.7) 
117 H 0 (0)    1 (0.6) 
168 E    1 (0.4) 0 (0) 
170 A    1 (0.4) 0 (0) 
170 T 0 (0)     2 (1.1) 
174 S    97 (40.8)   10 (5.6) 
aRAMs were classified according to the geno2pheno mutation list (March 2015 version) with 274 
the addition of Q80L (reference 11). Bold indicates major mutations for genotype 1/1a.  275 
276 
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Figure 1. Phylogenetic analysis of HCV-1a NS3 sequences from the United Kingdom, where 277 
green indicates sequences from the North-West and yellow indicates sequences from the 278 
South-East of England. The global reference dataset was derived from Los Alamos HCV 279 
database (March 2015; see supplementary file for accession numbers) and comprises 280 
sequences from the rest of Europe (in red) and North America (in blue). Nodes with bootstrap 281 
support values ≥90% are indicated with an asterisk.   282 
283 
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Figure 2. A HCV transmission cluster in the South-East of England, comprising 20 HCV-1a 284 
NS3 sequences (in yellow). Sequences from the rest of Europe and North America are shown 285 
in red and blue respectively. Nodes with bootstrap support values ≥90% are indicated with an 286 
asterisk. 287 
 288 
 289 
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